KAPIL COTEX LTD.

Skybiotech Healthcare Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ended June 30, 2026. This measure aligns with SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's internal code of conduct. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Skybiotech Healthcare Ltd has announced the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. The Board of Directors approved the results in their meeting held on May 30, 2026, which commenced at 05:00 PM and concluded at 07:15 PM. The audit report and limited review report issued by the statutory auditors were also taken on record.

Skybiotech Healthcare Ltd has announced a meeting of its Board of Directors scheduled for May 30, 2026, to consider and approve the audited financial results and limited review report for the quarter and year ended March 31, 2026. The meeting will also address any other business with the chair's permission.

Skybiotech Healthcare Ltd has announced the closure of its trading window for considering and approving the audited financial results for the quarter and year ended on 31st March 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's Code of Conduct for Prevention of Insider Trading and Code of Corporate Disclosure Practices. The trading window will remain closed from 1st April 2026 till the completion of 48 hours after the declaration of the audited financial results. All designated persons and their immediate relatives are advised not to enter into any transaction involving dealing or trading in the company's shares during this period.

Skybiotech Healthcare Ltd, formerly known as Kapil Cotex Limited, has submitted its un-audited financial results for the quarter ended on 31st December, 2025. The results were approved by the Board of Directors at their meeting held on Saturday, 14th February, 2026. The company is in the process of filing the financial results in the form of Integrated Financials within the stipulated time from the conclusion of the board meeting. The un-audited financial results (standalone and consolidated) for the quarter ended 31st December, 2025, have been reviewed by SPD AND ASSOCIATES CHARTERED ACCOUNTANTS.

Skybiotech Healthcare Ltd, formerly known as Kapil Cotex Limited, announced its unaudited financial results for the quarter and nine months ended 31st December 2025. The company's total expenses decreased by 0.48% compared to the same period last year, leading to a profit before exceptional items and tax of INR 25.70 crores. The company's net profit for the quarter was INR 5.96 crores. The company's name was changed on the Ministry of Corporate Affairs (MCA) portal on 7th November 2025.

Skybiotech Healthcare Ltd has announced a Board of Directors meeting on February 14, 2026. The agenda includes the approval of the unaudited financial results and limited review report for the quarter ending on December 31, 2025. This is in accordance with the SEBI (LODR) Regulations, 2015, Regulation 29(1) (a).

Kapil Cotex Ltd has announced the closure of its trading window in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the company's Code of Conduct for the Prevention of Insider Trading and Code of Corporate Disclosure Practices. The closure will be effective from 1st January, 2026 until 48 hours after the declaration of the unaudited Financial Results for the Quarter ended 31st December, 2025. All Designated Persons and their immediate relatives are advised not to engage in any transaction involving dealing or trading in the company's shares during this period.

Kapil Cotex Ltd, now known as Skybiotech Healthcare Limited, has announced its revised un-audited financial results for the quarter ended on 30th September, 2025. The board of directors approved the un-audited financial results (standalone and consolidated) for the half year ended on the same date. The revision was due to the non-attachment of the Consolidated Balance and Cash flow statement in the original submission. The limited review report was issued by the statutory auditors of the company.

Kapil Cotex Ltd, now known as Skybiotech Healthcare Limited, has announced its un-audited financial results for the quarter and half year ended on 30th September 2025. The company reported a net loss of Rs. 32.14 Lakhs for the quarter ended on 30th September 2025. The financial results were reviewed and approved by the Board of Directors in a meeting held on 14th November 2025. The company's management is responsible for preparing the statement in accordance with Ind AS 34, Companies Act, 2013 and other applicable accounting principles.